Assistant Professor of Internal Medicine

Von Visger JonAssistant Professor of Internal Medicine
Division of Nephrology

Comprehensive Transplant Center Pre-Transplant Office 
Brain and Spine Hospital

300 W. 10th Ave.
11th Floor
Columbus, OH 43210-1280

Research Interests: 

  • Acute renal failure
  • Delayed graft function
  • Antibody rejection

Current Research: While novel therapies often require novel drugs, sometimes it only requires novel approaches of current therapy. I have recently applied for an IND application for the use of an already FDA-approved drug, Belatacept, in the management of DGF.

I have already attained FDA approval for proceeding with my investigator initiated DGF protocol under my own IND application, and currently await our own institutional IRB application and budgetary approval from Bristol-Myers Squibb to move forward. I find that I am most excited to be applying therapy at the patient level in a translational than staying at the benchside. To date, there has yet to be a successful attempt at improving DGF outcomes, and the Belatacept trial has the potential for a landmark study. 

In a second, yet to be funded clinical trial, I am working with collaborators across several disciplines to evaluate a novel biological detection process using immunologically modified field-effect transistors. These have the potential to detect picomolar levels of inflammatory cytokines that might be used to diagnose rejection in biologic fluids.

Background: I have an extensive laboratory research background. My initial intent when I came to OSU in 2005 was to spend more time doing lab research on the traditional tenure track. I have since changed to the clinical track and redirected my efforts toward more translational research, applying my basic science experience toward clinical studies.

Despite dwindling NIH support for research, I have been resourceful enough to have had some reasonable success in bringing and completing clinical and translational studies here at Ohio State. While industry-sponsored studies appear to be the growing trend, I still intend to compete for the limited remaining NIH funds.

As one of the largest national kidney transplant centers, Ohio State has the potential to provide significant resources for career development, in both patient volume for clinical experience as well as data collection for clinical trials. This is why I came to OSU.


  • Medical Degree: University of Maryland School of Medicine
  • PhD: University of Maryland School of Medicine, neuroscience and anatomy
  • Residency: General Medicine, University of Maryland Health Center
  • Fellowship: Nephrology, Massachusetts General Hospital


  • Certificate of Excellence in Patient Service, The Ohio State University Wexner Medical Center, 2010 – 2012
  • Patent: Jon Von Visger, Amin Arnaout, Peter Linde, Alejandro Morales. Devise system of isolation and characterize integrated cells after engraftment. “Kidney Precursor Stem Cells Flk1+, Sca-1+.” Harvard. Filed 2006, and Patent No. 2232
  • Book: Von Visger J. Studies Relating to Neural Regeneration: 1. A Neurite-Promoting Factor Derived From Striated Muscle, and 2. Differentiation of Progenitor Cells for Newborn Rat Forebrain. Baltimore, MD, US|USA: University Microfilms Inc., January 1996

Share this Page